Panageas KS - Search Results

1

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A. Iwamoto FM, et al. Among authors: panageas ks. Neuro Oncol. 2011 Nov;13(11):1244-51. doi: 10.1093/neuonc/nor117. Epub 2011 Aug 10. Neuro Oncol. 2011. PMID: 21831900 Free PMC article.

2

Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status.

Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Ferrone CR, et al. Among authors: panageas ks. Ann Surg Oncol. 2002 Aug;9(7):637-45. doi: 10.1007/BF02574479. Ann Surg Oncol. 2002. PMID: 12167577

3

Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection.

Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB. Schrag D, et al. Among authors: panageas ks. Ann Surg. 2002 Nov;236(5):583-92. doi: 10.1097/00000658-200211000-00008. Ann Surg. 2002. PMID: 12409664 Free PMC article.

4

Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection.

Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Schrag D, et al. Among authors: panageas ks. J Surg Oncol. 2003 Jun;83(2):68-78; discussion 78-9. doi: 10.1002/jso.10244. J Surg Oncol. 2003. PMID: 12772198

5

The effect of clustering of outcomes on the association of procedure volume and surgical outcomes.

Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. Panageas KS, et al. Ann Intern Med. 2003 Oct 21;139(8):658-65. doi: 10.7326/0003-4819-139-8-200310210-00009. Ann Intern Med. 2003. PMID: 14568854

6

Delayed neurotoxicity in primary central nervous system lymphoma.

Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE. Omuro AM, et al. Among authors: panageas ks. Arch Neurol. 2005 Oct;62(10):1595-600. doi: 10.1001/archneur.62.10.1595. Arch Neurol. 2005. PMID: 16216945

7

Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis.

Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE. Panageas KS, et al. Cancer. 2005 Dec 1;104(11):2466-72. doi: 10.1002/cncr.21481. Cancer. 2005. PMID: 16240449 Free article.

8

Variates of survival in metastatic uveal melanoma.

Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Rietschel P, et al. Among authors: panageas ks. J Clin Oncol. 2005 Nov 1;23(31):8076-80. doi: 10.1200/JCO.2005.02.6534. J Clin Oncol. 2005. PMID: 16258106

9

Systemic high-dose intravenous methotrexate for central nervous system metastases.

Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, Raizer JJ. Lassman AB, et al. Among authors: panageas ks. J Neurooncol. 2006 Jul;78(3):255-60. doi: 10.1007/s11060-005-9044-6. J Neurooncol. 2006. PMID: 16344918 Clinical Trial.

10

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC. Hormigo A, et al. Among authors: panageas ks. Clin Cancer Res. 2006 Oct 1;12(19):5698-704. doi: 10.1158/1078-0432.CCR-06-0181. Clin Cancer Res. 2006. PMID: 17020973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters